Sireau Labs is engineering solutions for rare diseases with science that is at the forefront of precision medicine. We are in a daily race to save lives stolen or impacted by rare disease.
Sireau Labs is engineering solutions for rare diseases with science that is at the forefront of precision medicine. We are in a daily race to save lives stolen or impacted by rare disease.
A rare disease patient group and Sireau Labs discuss the potential to use mRNA therapy as a treatment for their rare disease.
If it looks possible, the rare disease patient group and Sireau Labs agree a programme of pre-clinical and early clinical work using mRNA technology, with milestones, deliverables and a budget.
The rare disease patient group raises the funds needed.
Sireau Labs and the rare disease patient group collaborate with a pharma company to take the treatment through late phase clinical trials.
If the studies are successful and marketing authorisation is obtained, Sireau Labs provides a fair share of the profit it receives to the rare disease patient group.
The rare disease patient group can reinvest this money into other research and patient support.
The current SARS Cov.2 pandemic has accelerated the use of messenger ribonucleic acid (mRNA) as a vaccine. mRNA is a single-stranded.
READ MORE
As well as working on AKU, we will focus on other rare genetic diseases. We are confident that our strategy will become a paradigm for the management of rare monogenic diseases in general.
READ MORE